Clinical trial
Michelangelo - Oasis 5
NCT00139815 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00139815 |
|---|---|
| Title | Michelangelo - Oasis 5 |
| Official title | An International, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Fondaparinux Versus Enoxaparin in the Acute Treatment of Unstable Angina/Non ST-segment Elevation MI Acute Coronary Syndromes |
| Lead sponsor | GlaxoSmithKline, Industry |
| Collaborators | University of Chicago Organon Industry Sanofi Duke University |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | Fondaparinux, enoxaparin |
| Enrollment | 20,078 |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Aug 31, 2005 |
| Last update posted | Sep 15, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: